CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Veracyte Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Veracyte Inc
6000 Shoreline Court, Suite 300
Phone: (650) 243-6300p:650 243-6300 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: VCYTVCYT
Business Summary
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
8071 Medical laboratories
2835 In vitro and in vivo diagnostic substances
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Robert S.Epstein 68 1/1/2022 1/12/2015
Chief Executive Officer, Director Marc A.Stapley 54 6/8/2021 6/1/2021
Chief Financial Officer RebeccaChambers 46 7/19/2021 7/19/2021
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
VERACYTE LUMINY BIOTECH ENTREPRISES CASE 923 MARSEILLE FR
HalioDx SAS 163 Avenue de Luminy Marseille Cedex 9 France
Decipher Biosciences, Inc. 1038 Homer Street Vancouver BC Canada
3 additional Subsidiary records available in full report.

Business Names
Business Name
Allegro Diagnostics Corp.
C2i Genomics Ltd
C2i Genomics, Inc.
13 additional Business Names available in full report.

General Information
Number of Employees: 815 (As of 12/31/2023)
Outstanding Shares: 77,499,629 (As of 11/1/2024)
Shareholders: 38
Stock Exchange: NASD
Federal Tax Id: 205455398
Fax Number: (650) 243-6301
Email Address: info@veracyte.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024